A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED…

Overview of attention for article published in Trials, October 2022

Altmetric Badge

Mentioned by

news: 5 news outlets
blogs: 1 blog

policy: 1 policy source
twitter: 3 X users

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 15 Mendeley

Summary News Blogs Policy documents X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 2,464 followers.

New from #ERC_Research https://t.co/Cti8yjMb59 A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a tri

12 Oct 2022

Reply Repost Favourite

A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network htt

12 Oct 2022

Reply Repost Favourite

09 Oct 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.